Datamonitor's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.
Datamonitors' Scil Biomedicals GmbH Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Scil Biomedicals GmbH since January 2007.
– Provides intelligence on Scil Biomedicals GmbH's M&A, strategic partnerships and alliances, capital raising and private equity transactions. – Detailed reports of various financial transactions undertaken by Scil Biomedicals GmbH and its subsidiaries since 2007. – Information about key financial and legal advisors for Scil Biomedicals GmbH's financial deals transactions. – Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity.
This report includes Scil Biomedicals GmbH's contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.
The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Scil Biomedicals GmbH. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.
Reasons to Purchase:
– Access comprehensive financial deals data along with charts and graph covering M&A, private equity, and partnerships and alliances. – Form an independent opinion about Scil Biomedicals GmbH’s growth strategies through the organic and inorganic activities undertaken since 2007. – Track your competitors’ business structure and growth strategies.
Our reports have been used by over 10K customers, including:
176 pages •
By Global Industry Analysts
• Sep 2020
Global Fragment-based Drug Discovery Market to Reach $1.1 Billion by 2027 Amid the COVID-19 crisis, the global market for Fragment-based Drug Discovery estimated at US$568 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing at aCAGR of 10.4% over the period 2020-2027. Fragment Screening...
The cell therapy market will show rapid growth due to the increasing prevalence of chronic conditions, rising adoption of regenerative medicine and rise in the number of clinical studies pertaining to the development of cellular therapies. Chronic diseases and conditions are on the rise worldwide. According to the World Health Organization,...
Myasthenia Gravis Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Myasthenia Gravis Global Clinical Trials Review, H2, 2020" provides an overview of Myasthenia Gravis Clinical trials scenario.This report provides top line data relating to the clinical trials on Myasthenia...
Global Autoimmune Partnering 2014 to 2020 provides the full collection of Autoimmune disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Autoimmune partnering deals Financial deal terms for headline, upfront and royalty by stage of development Autoimmune partnering...
The global primary cells market is projected to reach USD 1,613 million by 2025 from USD 970 million in 2020, at a CAGR of 10.7% during the forecast period. Market growth is driven by the rising prevalence of cancer, the rapid growth in the biotechnology & biopharmaceutical industries, growing focus on R&D, recent developments in stem cell...
House Dust Mite Allergy Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “House Dust Mite Allergy Disease - Global Clinical Trials Review, H2, 2020" provides an overview of House Dust Mite Allergy Clinical trials scenario.This report provides top line data relating...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.